Added to YB: 2025-11-26
Pitch date: 2025-11-23
NKTR [bullish]
Nektar Therapeutics
+35.66%
current return
Author Info
No bio for this author
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
Market Cap
$1.9B
Pitch Price
$55.08
Price Target
207.00 (+177%)
Dividend
N/A
EV/EBITDA
-14.51
P/E
-8.73
EV/Sales
29.18
Sector
Pharmaceuticals
Category
growth
$NKTR Deep Dive
NKTR: Rezpeg AA readout represents free call option on $1.2B market cap. >50% PoS based on: 1) AtD Ph2 proved skin-homing Treg expansion 2) Castela pilot showed dramatic hair regrowth with sustained IL-2 3) Only needs 20-25% efficacy to win safety-first market vs JAK black box warnings. Jefferies PT $207 (281% upside).
Read full article (5 min)